The cardiac drug maker has set a $15m target for the round, and has now raised about $110m altogether
US-based biopharmaceutical company Sorbent Therapeutics has raised $6.5m of a $15m series D round that has so far featured reinvestment from Novartis Venture Fund, the corporate venturing unit of Switzerland-based drugs company Novartis.
Other existing investors that contributed to the round include venture capital firms CMEA Capital, ARCH Venture Partners, Sofinnova Ventures and AgeChem.
Sorbent has recently enrolled 275 patients with heart failure into the phase 2b clinical trial of CLP-1001, a drug that aims to reduce cardiac disease by…
